 The aim of our study is to see whether removal of s-Flt1 may improve perinatal death in women with very early severe preeclampsia at less than 26 weeks gestation Patients and methods Phase II trial. Women with singleton pregnancy having severe preeclampsia at 23-2567 weeks gestation. Women under 18 years, with multiples, or severe fetal growth restriction less than 5th centile, or abnormal fetal heart rate, or maternal complications abruption, eclampsia, HELLP syndrome, pulmonary edema, DIC, liver hematoma are excluded from the study. After blood pressure and maternal stabilization, women are approached for information and if they agree, to sign the trial consent. 